Maintenance of intestinal epithelium structural integrity and mucosal leukocytes during chemotherapy by oral administration of muramyl tripeptide phosphatidylethanolamine.
The systemic administration of doxorubicin (DXR) decreases the number of epithelial cells and leukocytes in the small intestine of mice. Oral administration of muramyl tripeptide phosphatidylethanolamine (MTP-PE) prevented both disruption of intestinal architecture, and a decrease in the number of macrophages, and it induced the expression of IL-6, G-CSF, GM-CSF, and TNF-alpha in the intestinal tissue. The data suggest that the oral administration of MTP-PE can prevent chemotherapy-induced toxicity to the intestinal mucosa and hence infections due to translocation of aerobic bacteria from the intestine to the blood.
Killion
J J
JJ
Department of Cell Biology, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
Bucana
C D
CD
Radinsky
R
R
Dong
Z
Z
O'Reilly
T
T
Bilbe
G
G
Tarcsay
L
L
Fidler
I J
IJ
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000284:Administration, Oral; D000818:Animals; D016207:Cytokines / Q000235:genetics; D004317:Doxorubicin / Q000633:toxicity; D005260:Female; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000473:pathology; D007962:Leukocytes / Q000187:drug effects*; D051379:Mice; D008810:Mice, Inbred C57BL; D010714:Phosphatidylethanolamines / Q000008:administration & dosage / Q000494:pharmacology*; D012333:RNA, Messenger / Q000032:analysis
D000276:Adjuvants, Immunologic; D016207:Cytokines; D010714:Phosphatidylethanolamines; D012333:RNA, Messenger; C037144:mifamurtide; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D004317:Doxorubicin